author-photo

Neil Rabin

University College London
University College London Hospitals NHS Foundation Trust
University College Hospital

127

Papers

1638

Citations

Citation Trend

Filter By

Papers (127) Sort By

Journal Conference Others

Impact of COVID-19 on peripheral blood stem cell mobilization for myeloma patients.

2021 Leukemia & Lymphoma
Show All
- Source
- Cite
- Save
Citations (0)
Using depth of response to stratify patients to front line Autologous Stem Cell Transplant: results of the phase II PADIMAC Myeloma Trial.

2021 British Journal of Haematology
Show All
- Source
- Cite
- Save
Citations (1)
Health‐related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial

2021 British Journal of Haematology
Show All
- Source
- Cite
- Save
Citations (1)
Ixazomib with lenalidomide and dexamethasone for patients with relapsed multiple myeloma: impact of 17p deletion and sensitivity to proteasome inhibitors from a real world data-set.

2021 Leukemia & Lymphoma
Show All
- Source
- Cite
- Save
Citations (0)
Outcomes of relapse in patients with deferred autologous stem cell transplant after achieving at least very good partial response following bortezomib, adriamycin, dexamethasone chemotherapy for newly diagnosed multiple myeloma in the phase II PADIMAC trial

2021 British Journal of Haematology
Show All
- Source
- Cite
- Save
Citations (0)
OAB-047: Plasma cell disorder patients are left vulnerable after one dose of the BNT162b2 mRNA or the ChAdOx-nCOV-19 COVID-19 vaccines

2021 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (0)
Salvage second autologous stem cell transplant for relapsed multiple myeloma in the novel agent era benefits a subset of patients: single-center UK experience.

2021 Leukemia & Lymphoma
Show All
- Source
- Cite
- Save
Citations (0)
Defining Unmet Need Following Lenalidomide Refractoriness: Real-World Evidence of Outcomes in Patients With Multiple Myeloma

2021 Frontiers in Oncology
Show All
- Source
- Cite
- Save
Citations (0)
P-039: Adaptation of a myeloma minimal residual disease multi-parametric flow assay for real world practice

2021 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (0)
Serological response to the BNT162b2 mRNA or ChAdOx1 nCoV-19 COVID-19 vaccine after first and second doses in patients with plasma cell disorders: influence of host and disease factors.

2021 British Journal of Haematology
Show All
- Source
- Cite
- Save
Citations (0)